[
    [
        {
            "time": "2020-09-08",
            "original_text": "英国：阿斯利康暂停新冠疫苗试验是挑战，不一定阻碍研发进程",
            "features": {
                "keywords": [
                    "阿斯利康",
                    "新冠疫苗",
                    "暂停",
                    "研发进程"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "英国：阿斯利康暂停新冠疫苗试验是挑战，不一定阻碍研发进程",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-09-08",
            "original_text": "首现Ⅲ期临床试验暂停案例 新冠疫苗研发赛道分化",
            "features": {
                "keywords": [
                    "Ⅲ期临床",
                    "暂停",
                    "新冠疫苗",
                    "研发赛道"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "首现Ⅲ期临床试验暂停案例 新冠疫苗研发赛道分化",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-09-08",
            "original_text": "一大利空袭来：疫苗龙头盘中大跌近20% 概念股最高回撤已超40%",
            "features": {
                "keywords": [
                    "利空",
                    "疫苗龙头",
                    "大跌",
                    "回撤"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "一大利空袭来：疫苗龙头盘中大跌近20% 概念股最高回撤已超40%",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-09-08",
            "original_text": "接种者疑出现严重不良反应，全球首次暂停进入三期临床的新冠疫苗",
            "features": {
                "keywords": [
                    "接种者",
                    "不良反应",
                    "暂停",
                    "三期临床",
                    "新冠疫苗"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "接种者疑出现严重不良反应，全球首次暂停进入三期临床的新冠疫苗",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 10,
                "Impact": 10,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-09-08",
            "original_text": "向好信号连续两天反弹",
            "features": {
                "keywords": [
                    "向好信号",
                    "反弹"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "向好信号连续两天反弹",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-09-08",
            "original_text": "搜狐医药 | 阿斯利康临床三期疫苗试验叫停，康泰生物股价跳水",
            "features": {
                "keywords": [
                    "阿斯利康",
                    "临床三期",
                    "叫停",
                    "康泰生物",
                    "股价跳水"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "搜狐医药 | 阿斯利康临床三期疫苗试验叫停，康泰生物股价跳水",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-09-08",
            "original_text": "创业板两只千亿龙头跌超10%拖累基金",
            "features": {
                "keywords": [
                    "创业板",
                    "千亿龙头",
                    "跌超",
                    "基金"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "创业板两只千亿龙头跌超10%拖累基金",
                "Correlation": 5,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-09-08",
            "original_text": "【A股收盘综述】低价股放量溃退，创业板综指收跌4.71%成交金额首超4000亿元",
            "features": {
                "keywords": [
                    "A股",
                    "低价股",
                    "创业板综指",
                    "放量溃退",
                    "成交金额"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【A股收盘综述】低价股放量溃退，创业板综指收跌4.71%成交金额首超4000亿元",
                "Correlation": 4,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]